We are excited to share the news that NovoPedics' total meniscus replacement device currently in development recently received Breakthrough Device Designation from the U.S. Food and Drug Administration.
Click to view:
Novopedics press release
FVCG invested in NovoPedics in 2013.
We are excited to share the news that Visikol has been acquired by CELLINK. Visikol was founded in 2016 by entrepreneurs at Rutgers University. Visikol is a contract research services company focusing on accelerating the discovery and development of therapeutics by providing pharmaceutical and biotech companies with best-in-class cell culture, 3D tissue imaging, multiplex imaging and digital pathology services.